Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from PolyPid ( (PYPD) ).
On July 15, 2025, PolyPid Ltd. announced the development of a long-acting GLP-1 receptor agonists delivery platform aimed at the diabetes and weight loss market. This platform is designed to release GLP-1 for approximately 60 days, offering a significant improvement over current weekly injections. This innovation could potentially transform patient care by improving medication adherence and outcomes in the rapidly expanding diabetes and weight management markets, which are projected to reach $100 billion by 2030.
The most recent analyst rating on (PYPD) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on PolyPid stock, see the PYPD Stock Forecast page.
Spark’s Take on PYPD Stock
According to Spark, TipRanks’ AI Analyst, PYPD is a Neutral.
PolyPid’s score reflects significant financial challenges, including consistent losses and negative equity. While the company’s clinical advancements and financing efforts are promising, they are not sufficient to offset the financial risks. The stock exhibits neutral technical indicators and an unattractive valuation, limiting its appeal to investors.
To see Spark’s full report on PYPD stock, click here.
More about PolyPid
PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through its proprietary PLEX technology, which enables controlled, prolonged-release of therapeutics. The company is advancing its lead product candidate, D-PLEX100, for preventing surgical site infections and is exploring treatments for solid tumors with OncoPLEX.
Average Trading Volume: 499,865
Technical Sentiment Signal: Sell
Current Market Cap: $34.45M
For a thorough assessment of PYPD stock, go to TipRanks’ Stock Analysis page.